Literature DB >> 17944000

Mortality in schizophrenia.

Pascal Auquier1, Christophe Lançon, Frédéric Rouillon, Malcolm Lader.   

Abstract

Schizophrenia is a life-threatening disease associated with mortality rates that are two to three times higher than those expected/observed in the general population. It is associated with high levels of suicide, particularly in young male patients soon after diagnosis. Delays in treating schizophrenia could contribute to the high number of suicides during this period. However, approximately two-thirds of the excess mortality is caused by natural deaths. Patients with schizophrenia die from the same diseases as people in the general population. The number of deaths caused by cardiovascular disease, as in the general population, is high and could be reduced by the modification of certain lifestyle factors, such as diet and exercise. Careful monitoring of patients' weight, blood pressure, blood glucose levels and serum lipid levels will not only provide an opportunity to educate patients about lifestyle choices that contribute to cardiovascular disease but will also give them a better chance of receiving early treatment for disorders that contribute to cardiovascular disease, such as obesity, type 2 diabetes, hypertension and dyslipidaemia. Careful selection of antipsychotic drugs, some of which are associated with side effects such as weight gain and cardiac disorders, will also help reduce co-morbidity and mortality among patients with schizophrenia. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2007        PMID: 17944000     DOI: 10.1002/pds.1496

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

Review 1.  Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review.

Authors:  Nick Verhaeghe; Jan De Maeseneer; Lea Maes; Cornelis Van Heeringen; Lieven Annemans
Journal:  Int J Behav Nutr Phys Act       Date:  2011-04-11       Impact factor: 6.457

Review 2.  New wine in old bottle: late-life psychosis.

Authors:  Alana Iglewicz; Thomas W Meeks; Dilip V Jeste
Journal:  Psychiatr Clin North Am       Date:  2011-06

Review 3.  The Long Non-Coding RNA GOMAFU in Schizophrenia: Function, Disease Risk, and Beyond.

Authors:  Paul M Zakutansky; Yue Feng
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

4.  Cigarette smoking and mortality risk in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Heidi J Wehring; Fang Liu; Kristen M Mackowick; Douglas L Boggs; Kimberly R Warren; Stephanie Feldman; Joo-Cheol Shim; Raymond C Love; Lisa Dixon
Journal:  Schizophr Bull       Date:  2009-12-17       Impact factor: 9.306

5.  Using patient-facing kiosks to support quality improvement at mental health clinics.

Authors:  Amy N Cohen; Matthew J Chinman; Alison B Hamilton; Fiona Whelan; Alexander S Young
Journal:  Med Care       Date:  2013-03       Impact factor: 2.983

6.  Guideline-concordant antipsychotic use and mortality in schizophrenia.

Authors:  Bernadette A Cullen; Emma E McGinty; Yiyi Zhang; Susan C Dosreis; Donald M Steinwachs; Eliseo Guallar; Gail L Daumit
Journal:  Schizophr Bull       Date:  2012-10-30       Impact factor: 9.306

7.  Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia.

Authors:  Han-Yi Ching; Shang-Liang Wu; Wen-Chi Chen; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-10       Impact factor: 2.629

8.  A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia.

Authors:  Milawaty Nurjono; Jimmy Lee; Siow-Ann Chong
Journal:  Clin Psychopharmacol Neurosci       Date:  2012-08-31       Impact factor: 2.582

9.  A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches.

Authors:  Samuel Sarrazin; Florence Louppe; Raphael Doukhan; Franck Schürhoff
Journal:  Ann Gen Psychiatry       Date:  2015-12-10       Impact factor: 3.455

10.  Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis.

Authors:  Yanli Liu; Zezhi Li; Meixia Zhang; Youping Deng; Zhenghui Yi; Tieliu Shi
Journal:  BMC Med Genomics       Date:  2013-01-23       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.